| Name | Title | Contact Details |
|---|
Headquartered in Jacksonville, FL, Healogics is the nation`s largest provider of advanced wound care services. Healogics and its affiliated companies manage a network of Wound Care Centers® through-out the United States and the United Kingdom. Healogics technology-enabled wound care model supports the critical connection between patients with chronic wounds and multi-disciplinary teams for continuous, collaborative, patient-centered care.
Health Forum is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Want to sell your vet hospital? We are a veterinarian-owned and managed network of animal hospitals for veterinarians who wish to sell their veterinary practice. Offering veterinary career opportunities. Call 205-453-4760 today!
Sterling Life Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.